Interim Report January – March 2026

Avarda reported solid Q1 2026 operating profit of SEK 244.6 million, up 30% year over year, with earnings per share rising 47% to SEK 3.17 and adjusted EPS up 32% to SEK 2.89. Loans to the public reached SEK 24.5 billion, up 20% in local currencies versus March 2025, while the cost/income ratio improved to 35.3% from 37.3% and return on equity increased to 26.1%. The update points to stronger profitability and operating efficiency, though it is primarily a factual earnings release rather than a major market-moving event.

Analysis

The quality signal here is not just growth, but operating leverage: profitability is expanding faster than the loan book, which implies Avarda is still benefiting from a favorable mix shift and disciplined funding/cost control rather than simply buying volume. In banking, that matters more than headline asset growth because it tells you incremental assets are still producing attractive marginal returns, and the improved cost/income ratio suggests the business has not yet hit diminishing returns on scale.

The second-order read is competitive. A specialized consumer-credit lender with improving ROE in a higher-rate environment can pressure weaker fintech lenders and bank card units that rely on thinner spreads or heavier acquisition spend. If Avarda can keep loan growth elevated without a matching rise in credit losses, it may force rivals to choose between defending share and defending margins — a dynamic that usually shows up with a lag of 1-3 quarters in industry pricing and underwriting standards.

The key risk is that this is late-cycle earnings quality: strong current spreads can mask underwriting slippage that only appears when vintages season. The numbers can stay momentum-positive for months, but the reversal catalyst is usually a modest rise in delinquencies or funding costs, not a headline recession. Watch for any sign that growth is coming from lower-quality cohorts or shorter-tenor products; that is where ROE can compress abruptly once credit normalization begins.

Consensus may be underestimating how much of this is a regime shift versus a one-quarter beat. If management is truly clarifying structure and offering, that can reduce a persistent valuation discount by making earnings easier to underwrite, especially for investors who penalize opaque fintech-credit hybrids. The upside is not just earnings momentum; it is multiple expansion if the market starts treating Avarda as a cleaner, more predictable lender rather than a complex growth story.

Key Decisions for Investors

• If a liquid line exists, initiate a tactical long in Avarda on any post-print consolidation, targeting a 1-3 month hold; the setup favors continued estimate revisions if credit metrics remain stable and the main risk is a delayed delinquency inflection.
• Relative-value long Avarda vs. a weaker Nordic consumer-finance/fintech lender with higher cost/income or lower ROE; the spread trade benefits if the market rewards operating leverage and penalizes less efficient peers over the next 1-2 quarters.
• Buy near-dated downside protection or trim longs if funded exposure is rising faster than earnings quality indicators; the trade-off is attractive because credit deterioration typically appears with a lag, so cheap hedges can protect against a sudden reassessment.
• Use any earnings-season strength to add only if management guides to stable funding costs and unchanged loss assumptions; otherwise, fade strength into the print because margin expansion is the part most likely to mean-revert over 6-12 months.
• Monitor for a rerating catalyst: if transparency improves and execution stays consistent for two consecutive quarters, shift from tactical long to core watchlist candidate, as multiple expansion can outpace incremental EPS growth.